The partnership will expand access to high-quality human and animal-derived biological materials for drug discovery and toxicology research in India
GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with BeCytes Biotechnologies. The partnership will expand access to high-quality human and animal-derived biological materials for drug discovery and toxicology research in India.
The collaboration leverages BeCytes’ specialised expertise in tissue procurement, primary cell isolation, and in vitro models, enabling Indian researchers to utilise cutting-edge tools for more predictive and translational studies.
As part of this partnership, GVRP will facilitate the availability of cryopreserved hepatocytes, hepatic and skin cells, subcellular fractions, and customized cell isolation services—critical resources for drug metabolism, safety assessment, and disease modelling.
“As India’s biomedical research landscape continues to expand, access to high-quality biological models remains a key challenge,” said Kalyan Korisapati, Co-Founder & Group CEO, GVRP. “By partnering with BeCytes, we are closing this gap and ensuring that researchers in India have seamless access to best-in-class hepatic cell models, including disease models such as NASH and Liver 3D Spheroids functional models, to advance their discoveries.”
BeCytes Biotechnologies, headquartered in Barcelona, Spain, has a proven track record of supplying primary human and animal-derived cells to researchers worldwide. Their expertise in cell characterization and in vitro model development ensures consistency and reliability, addressing a critical need in preclinical drug screening and toxicology studies.
“We are excited to collaborate with GVRP to expand our global reach and empower researchers in India with reliable cell-based solutions,” said Jordi Xapellí, CEO, BeCytes Biotechnologies “With GVRP’s established presence and commitment to research excellence, this partnership will drive impactful scientific advancements.”
